# Real-world Data (RWD) of Ramucirumab Plus Paclitaxel

> **NCT04915807** · — · UNKNOWN · sponsor: **Hallym University Medical Center** · enrollment: 222 (estimated)

## Conditions studied

- Gastric Cancer
- Gastroesophageal Junction Adenocarcinoma

## Interventions

- **DRUG:** Ramucirumab and paclitaxel
- **DRUG:** Taxane, irinotecan, or fluoropyrimidine-based single or combined chemotherapy

## Key facts

- **NCT ID:** NCT04915807
- **Lead sponsor:** Hallym University Medical Center
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-06
- **Primary completion:** 2022-09
- **Final completion:** 2023-09
- **Target enrollment:** 222 (ESTIMATED)
- **Last updated:** 2021-06-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04915807

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04915807, "Real-world Data (RWD) of Ramucirumab Plus Paclitaxel". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT04915807. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*